Back to School: How biopharma can reboot drug development. Access exclusive analysis here

1013 Chord
BioCentury & Getty Images

Finance

Chord launches with $16M to test MS drug cladribine in rare autoimmune disorders

Omega Funds is sole investor for Swiss start-up’s series A, reuniting firm with CEO Plitz 

Chord Therapeutics’ series A round reunites Omega Funds with the Swiss start-up’s CEO, Tom Plitz, the former CSO

Read the full 492 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE